1 active not recruiting, 1 completed, 1 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Composite Lymphoma: new trials by email Literature Review of Composite Lymphoma trials Research Report on Composite Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| Italian Multicenter Retrospective Observational Study on Transformed Lymphomas Non-Hodgkin Lymphoma Transformed Recurrent | Unknown | A.O.U. Città della Salute e della Scienza | 180 | 2017-11-01 | 2017-11-24 | |
| Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Composite Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Completed | University of Washington | 30 | 2015-11-24 | 2020-10-14 |
Lymphoma, Follicular (3) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Complex and Mixed (3) · Lymphoma, B-Cell (2)
CT-P10 (2) · Rituximab (2) · ALX148 (1) · Cyclophosphamide (1) · Doxorubicin (1) · Lenalidomide (1) · Prednisone (1) · Vincristine (1) · deltacortene (1) · pembrolizumab (1) · prednylidene (1)
A.O.U. Città della Salute e della Scienza (1) · M.D. Anderson Cancer Center (1) · University of Washington (1)
United States (2) · Italy (1)
Barbara Botto, MD (1) · Paolo Strati, MD (1) · Stephen Smith (1)
P30CA015704 (1)